Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?

Abstract

Gene and cell therapy products approved over the past decade in Europe and North America have provided new therapeutic options for single gene disorders and for hematologic malignancies. Lessons learned, and limitations identified, are reviewed.